Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL
The HemOnc Pulse
00:00
BIS Antibodies in Oncology: Focus on CD3 and CD20 Targeting
This chapter delves into the efficacy and toxicity of CD3 and CD20 targeting antibodies in lymphoma treatments, with a spotlight on glutphimab in relapsed/refractory DLBCL. It also explores the concept of fixed duration therapy and compares glutphimab to other biospecific antibodies in large cell lymphoma.
Transcript
Play full episode
